Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12104/66120
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHoyo-Vadillo, C.
dc.contributor.authorVenturelli, C.R.
dc.contributor.authorGonzalez, H.
dc.contributor.authorRomero, E.
dc.contributor.authorCervantes, R.
dc.contributor.authorMata, N.
dc.contributor.authorOrtiz, A.C.
dc.contributor.authorRincon, V.
dc.contributor.authorZarate, F.
dc.contributor.authorSosa, C.
dc.contributor.authorRamirez-Mayans, J.
dc.date.accessioned2015-11-19T18:51:01Z-
dc.date.available2015-11-19T18:51:01Z-
dc.date.issued2005
dc.identifier.urihttp://hdl.handle.net/20.500.12104/66120-
dc.description.abstractProton pump inhibitors (PPIs) have been used recently for gastrointestinal esophageal reflux disease (GERD) in children older than one year with good results [1,2]. However, the pharmacokinetics of PPIs have not been studied in children less than two years old. The aim of our study was to evaluate the frequency of the main phenotypes of the metabolizing enzymes CYP2C19 and CYP3A4 in Mexican infants. Our results indicate no significant difference between the 0.5 and the 1.5 mg/kg doses. The percentage of CYP2C19- poor metabolizers was 17% in babies below 4 months and was not detected in children above 3 months. When a combined CYP2C19- and CYP3A4- phenotype was estimated, omeprazole levels were significantly higher in poor metabolizers than in extended metabolizers. The percentage of ultra-extensive metabolizers in children older than 3 months were 20% and 33% for CYP2C19 and CYP3A4 respectively, compared to only 6% and 9% respectively, in babies between 1 and 3 months old. In general children, under 4 months had higher omeprazole levels and an immature metabolism. Studies in children older than 2 years old have showed similar pharmacokinetics to adults. For children between 1 month old and up to 9 months, we suggest the use of the 0.5 mg/kg dose, since it prevents accumulation in poor metabolizers, caution is recommended to identify ultra-fast metabolizers, but this would require new studies.
dc.titleMetabolism of omeprazole after two oral doses in children 1 to 9 months old
dc.typeConference Paper
dc.relation.ispartofjournalProceedings of the Western Pharmacology Society
dc.relation.ispartofvolume48
dc.relation.ispartofpage108
dc.relation.ispartofpage109
dc.contributor.affiliationHoyo-Vadillo, C., Div. Pharmacology, Cinvestav, Mexico City, Mexico; Venturelli, C.R., Div. Pharmacology, Cinvestav, Mexico City, Mexico; González, H., CUCEI, University of Guadalajara, Guadalajara, Mexico; Romero, E., CUCEI, University of Guadalajara, Guadalajara, Mexico; Cervantes, R., Instituto Nacional de Pediatría, Mexico City, Mexico; Mata, N., Instituto Nacional de Pediatría, Mexico City, Mexico; Ortiz, A.C., Instituto Nacional de Pediatría, Mexico City, Mexico; Rincón, V., Instituto Nacional de Pediatría, Mexico City, Mexico; Zarate, F., Instituto Nacional de Pediatría, Mexico City, Mexico; Sosa, C., Instituto Nacional de Pediatría, Mexico City, Mexico; Ramírez-Mayans, J., Instituto Nacional de Pediatría, Mexico City, Mexico
dc.relation.isReferencedByScopus
dc.identifier.urlhttp://www.scopus.com/inward/record.url?eid=2-s2.0-30144434099&partnerID=40&md5=2188b280dca4c7758be49d4f2518fec7
Appears in Collections:Producción científica UdeG (prueba)

Files in This Item:
There are no files associated with this item.


Items in RIUdeG are protected by copyright, with all rights reserved, unless otherwise indicated.